Why eConsent Primes Studies & Patients for Success
September 12th 2022According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Quality control for human cell lines and other human samples manipulated ex vivo
August 25th 2022In this paper, learn about a variety of genetic analysis methods and how they’re valuable in ensuring that ex vivo human cells used for cell‑based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Download the white paper and read more about the importance of quality control (QC) for isolated human cells and tissues.
Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets
August 25th 2022For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs.
Seizing the Customer Experience Opportunity in Life Sciences
March 14th 2022To get a better understanding of how technology can power superior customer experiences, Salesforce commissioned research to explore what being customer-centric means for life sciences organizations and technology’s role in building stronger connections among people, data, and processes that ultimately lead to better health outcomes.
Smarter Signal Management: AI, big data, and predictive analytics
February 15th 2022What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.
The Next Domino: Automation, AI, and touchless safety case processing
February 15th 2022With the increasing volumes of adverse event reports and stagnant budgets, the time is now for a revolutionary change in drug and device safety case management. A robust management process is necessary for identifying and evaluating adverse events (AE) and reporting them properly to regulators.
Using ML, AI and RWD to Infer HCP Specialties
October 2nd 2021Pharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Shortening the Rare Disease Diagnostic Odyssey
October 2nd 2021Specialty and rare diseases have undefined patient populations with patients who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as diagnostic and treatment journeys that are not well-understood. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can improve outcomes at scale.